Lifescience Global

JCRUV1N1A04

Image

JCRUV1N1A04

Moving EGFR Targeted Therapy into the Induction Phase of the Management of Squamous Cell Carcinoma of the Head and Neck - Pages 14-21

Belisario A. Arango1, Bertha E. Sanchez2, Matthew C. Abramowitz3 and Edgardo S. Santos1

1Division of Hematology/Oncology, Sylvester Comprehensive Cancer Center/University of Miami Miller School of Medicine, Miami, FL; 2Department of Medicine, Henry Ford Hospital, Detroit, MI; and 3Department of Radiation Therapy, Sylvester Comprehensive Cancer Center/University of Miami Miller School of Medicine, Miami, FL, USA

DOI: http://dx.doi.org/10.6000/1929-2279.2012.01.01.04

Files

  • Additional Information

    Abstract: Many advances in the treatment of squamous cell carcinoma of the head and neck have occurred in the past few years. Since the advent of cetuximab, a chimeric monoclonal antibody against epidermal growth factor receptor, the search for other efficacious targeted therapies has awakened the interest and curiosity of researchers and clinicians. Initially, cetuximab demonstrated effectiveness as single agent in heavily pretreated patients diagnosed with head and neck cancer, and has demonstrated to improve locoregional control and survival when combined with radiotherapy. Thesuccess of cetuximab has transitioned to other settings and with different modalities such as in combination with other conventional cytotoxic agents in the metastatic setting, combined with radiation therapy as part of concurrent treatment, and lately, in combination with other agents in the induction phase of the sequential approach. In this review, we discuss all different modalities in combination with cetuximab and how cetuximab has been incorporated into other clinical settings with only one goal in mind: improve the survival rates of our patients.

    Keywords: Cetuximab, chemoimmunotherapy, concurrent chemoradiation, epidermal growth factor receptor, head and neck cancer, Human papilloma virus, induction therapy, organ preservation, radiation therapy, sequential approach.

    OUR STRENGTHS

    ♦  Worldwide readership
    ♦  High quality content
    ♦  Maximum visibility
    ♦  Efficient publishing
    ♦  Optional Open Access

    Publish your Research

    Survey

    As an author what type of publishing model you prefer?

    780
    Open Access
    493
    Optional Open Access
    338
    Subscription based
    5 Votes left